📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: IntraBio

1.1 - Company Overview

IntraBio Logo

IntraBio

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of biopharmaceutical therapies and candidates, including IB1001 (orally administered N-Acetyl-Leucine) for rare neurological disorders such as NPC, GM1/GM2 gangliosidosis and inherited cerebellar ataxias; IB2000 and IB5000 for Ménière’s disease with clinical efficacy and safety in observational studies; IB3000 (NAADP analogues/agonists) with pre-clinical potential for Type 2 Diabetes, autism and neurodegenerative disorders; IB4000 (UDCA) for NPC liver dysfunction.

Products and services

  • IB1001 Series: Orally administered, modified amino acid N-Acetyl-Leucine products engineered to treat rare neurological disorders including Niemann-Pick Disease Type C, GM1/GM2 gangliosidosis, and inherited cerebellar ataxias
  • IB3000 Series: Pre-clinical-stage NAADP analogues and agonists created with demonstrated potential for treating Type 2 Diabetes, autism, and neurodegenerative disorders
  • IB2000 Series: Observational-study–validated Diferuloylmethane analogues produced for Ménière’s disease, demonstrating clinical efficacy and safety in observational studies.

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to IntraBio

Adelia Therapeutics Logo

Adelia Therapeutics

HQ: United States Website
  • Description: Provider of a drug discovery platform developing proprietary tryptamine-based therapeutics to treat central nervous system (CNS) disorders.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Adelia Therapeutics company profile →
Eleusian Biosciences Logo

Eleusian Biosciences

HQ: Canada Website
  • Description: Provider of therapeutics in development for multiple pathological psychological diseases, based on psilocybin plus N-acetylcysteine (NAC) compounds.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Eleusian Biosciences company profile →
Envoy Therapeutics Logo

Envoy Therapeutics

HQ: United States Website
  • Description: Provider of drug discovery focused on novel drugs for neurological and psychiatric diseases, using bacTRAP technology to identify proteins in vivo produced by specific cell types without isolating those cells, aiming for superior efficacy and fewer side effects.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Envoy Therapeutics company profile →
Pulsar Vascular Logo

Pulsar Vascular

HQ: United States Website
  • Description: Provider of an endovascular platform addressing bifurcation aneurysms, offering the PulseRider Neck Reconstruction Device, a neck-bridge solution designed to span the aneurysm neck and support and stabilize an embolic coil mass.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Pulsar Vascular company profile →
Cerus Endovascular Logo

Cerus Endovascular

HQ: United Kingdom Website
  • Description: Provider of interventional neuroradiology devices and delivery systems, including the e-clipse aneurysm occlusive device that addresses neurovascular aneurysm procedures currently attempted by surgical clipping, minimally invasive metal coils, and liquid embolics.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Cerus Endovascular company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for IntraBio

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to IntraBio

2.2 - Growth funds investing in similar companies to IntraBio

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for IntraBio

4.2 - Public trading comparable groups for IntraBio

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to IntraBio

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About IntraBio

What does IntraBio do?

IntraBio is a provider of biopharmaceutical therapies and candidates, including IB1001 (orally administered N-Acetyl-Leucine) for rare neurological disorders such as NPC, GM1/GM2 gangliosidosis and inherited cerebellar ataxias; IB2000 and IB5000 for Ménière’s disease with clinical efficacy and safety in observational studies; IB3000 (NAADP analogues/agonists) with pre-clinical potential for Type 2 Diabetes, autism and neurodegenerative disorders; IB4000 (UDCA) for NPC liver dysfunction.

Who are IntraBio's competitors?

IntraBio's competitors and similar companies include Adelia Therapeutics, Eleusian Biosciences, Envoy Therapeutics, Pulsar Vascular, and Cerus Endovascular.

Where is IntraBio headquartered?

IntraBio is headquartered in United States.

How many employees does IntraBio have?

IntraBio has 1,000 employees 🔒.

When was IntraBio founded?

IntraBio was founded in 2010 🔒.

What sector and industry vertical is IntraBio in?

IntraBio is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for IntraBio

Who are the top strategic acquirers in IntraBio's sector and industry

Top strategic M&A buyers and acquirers in IntraBio's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for IntraBio?

Top strategic M&A buyers groups and sectors for IntraBio include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in IntraBio's sector and industry vertical

Which are the top PE firms investing in IntraBio's sector and industry vertical?

Top PE firms investing in IntraBio's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in IntraBio's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in IntraBio's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in IntraBio's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to IntraBio include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in IntraBio's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for IntraBio?

The key public trading comparables and valuation benchmarks for IntraBio include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for IntraBio for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for IntraBio with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in IntraBio's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for IntraBio with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in IntraBio's' sector and industry vertical?

Access recent funding rounds and capital raises in IntraBio's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for IntraBio